Results 41 to 50 of about 78,996,387 (176)

Bioinformatic analyses of the three 5-HT1 serotonin receptors identified in this work (Eca-5-HT_1a, Mvo-5-HT_1a and Hmi-5-HT_1a, GenBank accession numbers MW535743, MW535744 and MW535745 respectively).

, 2021
A. The structural representation and prediction of residues of potential N-glycosylation of Eca-5-HT1a were obtained with the Protter program (http://www.enzim.hu/hmmtop/index.php).
Matias Preza (11681874), Federico Camicia (3799405), Jonathan S. Marchant (11642578), Ana M. Celentano (10225166), Ariel Naidich (11681871), Uriel Koziol (573293), Sang-Kyu Park (2658493), Augusto E. Bivona (4458598), Mara C. Rosenzvit (11681877), Hugo R. Vaca (10225163)   +9 more
core   +1 more source

A scoping review of adverse events associated with concomitant beta‐adrenoreceptor blockers and selective serotonin reuptake inhibitors

British Journal of Clinical Pharmacology, EarlyView.
Beta‐adrenoreceptor blockers (beta‐blockers) and selective serotonin reuptake inhibitors (SSRIs) are commonly used medications and often used together, such as for the treatment of anxiety. However, there is no recent review of any potential adverse events related to concomitant use of medicines from each group.
Ziyi Cai, James Sutton, Charlotte Archer, Caroline S. Copeland, Joseph Hayes, Charles E. Leonard, Nicky Lidbetter, Kenneth K. C. Man, Faraz Mughal, Ian C. K. Wong, Hayley C. Gorton   +10 more
wiley   +1 more source

Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity

Frontiers in Neuroscience, 2019
Major depressive disorder (MDD) is the most prevalent mental illness contributing to global disease burden. Selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the first-line treatment for MDD, but are only fully effective in 30% of patients and ...
Faranak Vahid-Ansari, Min Zhang, Amin Zahrai, Paul R. Albert   +3 more
doaj   +1 more source

Do preclinical seizure models predict success or failure in anti‐seizure drug development? A retrospective analysis of 89 compounds with divergent clinical outcomes for epilepsy

Epilepsia, EarlyView.
Abstract Anti‐seizure medication (ASM) discovery remains a major challenge despite over 30 commercially available options. One persistent obstacle for any promising candidate compound to successfully move from preclinical study to clinical approval has been the ambiguity in preclinical model selection.
Wolfgang Löscher, Melissa Barker‐Haliski   +1 more
wiley   +1 more source

Role of the 5-HT1A autoreceptor in the enhancement of fluvoxamine-induced increases in prefrontal dopamine release by adrenalectomy/castration in mice

Journal of Pharmacological Sciences, 2015
We have found that fluvoxamine-induced increases in prefrontal dopamine release are enhanced by adrenalectomy/castration and 5-HT1A receptors are involved in the enhancement.
Shigeru Hasebe, Naoki Hiramatsu, Yukio Ago, Kazuya Mori, Yuji Watabe, Hitoshi Hashimoto, Kazuhiro Takuma, Toshio Matsuda   +7 more
doaj   +1 more source

Ingestão de alimento após a ativação de receptores 5-HT1A do núcleo arqueado do hipotálamo e da área hipotalâmica lateral de ratas em duas fases do ciclo estral [PDF]

, 2009
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Neurociências, Florianópolis, 2009.O presente estudo examinou os efeitos da injeção local de metergolina (MET, antagonista de ...
Steffens, Sérgio Murilo
core  

Artificial Intelligence‐Driven Natural Product Drug Discovery: From Computational Genome Mining to Clinical Translation

Medicinal Research Reviews, EarlyView.
ABSTRACT Natural products (NPs) have historically yielded numerous therapeutic agents, yet their integration into modern drug discovery has been constrained by chemical complexity, low abundance, laborious dereplication, and limited target annotation.
Antonio Lavecchia
wiley   +1 more source

Structural Pharmacology of Bufotenine Derivatives in Activating the 5-HT1A Receptor for Therapeutic Potential in Depression and Anxiety

Research
The 5-HT1A receptor is a critical target in the treatment of depression and anxiety. Bufotenine derivatives, such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 5-hydroxy-N,N-dimethyltryptamine (5-OH-DMT), and 5-hydroxy-N,N,N-dimethyltryptamine—derived
Shu-jie Li, Qing-ning Yuan, Wen-yuan Wu, Zhi-han Chen, Duo Chen, Hong Shan, Qin-yu Chu, Wen Hu, Kai Wu, Tao Liu, Yu-yu Zhu, Li Hou, Jing Zhou, Jia Duan, Jin-ao Duan, H. Eric Xu, Hong-yue Ma   +16 more
doaj   +1 more source

Serotonergic Modulation of Absence-Like Seizures in Groggy Rats: a Novel Rat Model of Absence Epilepsy

Journal of Pharmacological Sciences, 2010
To explore the role of the serotonergic system in modulating absence seizures, we examined the effects of 5-HT1A and 5-HT2 agonists on the incidence of spike-and-wave discharges (SWD) in Groogy (GRY) rats, a novel rat model of absence-like epilepsy.
Yukihiro Ohno, Nobumasa Sofue, Takuji Imaoku, Eri Morishita, Kenta Kumafuji, Masashi Sasa, Tadao Serikawa   +6 more
doaj   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source